Suppr超能文献

紫花牡荆苷-四面体骨架核酸系统:用于急性肾损伤治疗的线粒体修复与抗氧化作用

Typhaneoside-Tetrahedral Framework Nucleic Acids System: Mitochondrial Recovery and Antioxidation for Acute Kidney Injury treatment.

作者信息

Yan Ran, Cui Weitong, Ma Wenjuan, Li Jiajie, Liu Zhiqiang, Lin Yunfeng

机构信息

State Key Laboratory of Oral Diseases, National Clinical Research Centre for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, P. R. China.

Sichuan Provincial Engineering Research Center of Oral Biomaterials, Chengdu, Sichuan 610041, China.

出版信息

ACS Nano. 2023 May 9;17(9):8767-8781. doi: 10.1021/acsnano.3c02102. Epub 2023 Apr 14.

Abstract

Acute kidney injury (AKI) is not only a worldwide problem with a cruel hospital mortality rate but also an independent risk factor for chronic kidney disease and a promoting factor for its progression. Despite supportive therapeutic measures, there is no effective treatment for AKI. This study employs tetrahedral framework nucleic acid (tFNA) as a vehicle and combines typhaneoside (Typ) to develop the tFNA-Typ complex (TTC) for treating AKI. With the precise targeting ability on mitochondria and renal tubule, increased antiapoptotic and antioxidative effect, and promoted mitochondria and kidney function restoration, the TTC represents a promising nanomedicine for AKI treatment. Overall, this study has developed a dual-targeted nanoparticle with enhanced therapeutic effects on AKI and could have critical clinical applications in the future.

摘要

急性肾损伤(AKI)不仅是一个全球范围内存在的问题,有着残酷的医院死亡率,而且是慢性肾脏病的独立危险因素及其进展的促进因素。尽管有支持性治疗措施,但目前尚无针对AKI的有效治疗方法。本研究采用四面体框架核酸(tFNA)作为载体,并结合巴戟天苷(Typ)来开发用于治疗AKI的tFNA-Typ复合物(TTC)。由于TTC对线粒体和肾小管具有精确的靶向能力、增强的抗凋亡和抗氧化作用以及促进线粒体和肾功能恢复,它是一种很有前景的用于治疗AKI的纳米药物。总体而言,本研究开发了一种对AKI具有增强治疗效果的双靶向纳米颗粒,未来可能具有关键的临床应用价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验